{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:17:19Z","timestamp":1768306639583,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the risk of developing systemic autoimmune diseases (SADs) among pediatric patients with juvenile idiopathic arthritis (JIA) treated with tumor necrosis factor inhibitors (TNFi) versus interleukin-6 inhibitors (IL-6i), based on real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective real-world cohort study using the TriNetX Research Network, which contains data from over 122 million patients. Individuals \u226418 years of age with a diagnosis of JIA who initiated TNFi or IL-6i therapy between January 1, 2013, and December 31, 2024, were included. Propensity score matching (1:1) was performed to balance baseline characteristics. The primary outcome was the incidence of SADs. Hazard ratios (HRs) were estimated using Cox proportional hazards models, and subgroup and sensitivity analyses were conducted to assess robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 1,192 patients were included in each cohort. The TNFi group demonstrated a significantly lower incidence of SADs than the IL-6i group (17 vs. 45 events; HR = 0.37, 95% CI: 0.20\u20130.63). Subgroup analyses showed consistent protective effects of TNFi across age, sex, and concomitant medication strata. Sensitivity analyses across three adjusted models confirmed the robustness of the findings, yielding HRs ranging from 0.28 to 0.46.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among pediatric patients with JIA, TNF inhibitor therapy was associated with a substantially lower risk of developing systemic autoimmune diseases compared with IL-6 inhibitor therapy. These findings may inform biologic selection and long-term safety considerations in pediatric rheumatologic practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1744226","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:36:00Z","timestamp":1768286160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative risk of systemic autoimmune diseases in juvenile idiopathic arthritis treated with TNF-\u03b1 or IL-6 inhibitors: a real-world cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Jih-Jin","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Teh","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Heng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23606","article-title":"Trends in population-based incidence and prevalence of juvenile idiopathic arthritis in manitoba, Canada","volume":"71","author":"Shiff","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23327","article-title":"Physical functioning, pain, and health-related quality of life in adults with juvenile idiopathic arthritis: A longitudinal 30-year followup study","volume":"70","author":"Tollisen","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B5","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14813","article-title":"New classification criteria for juvenile idiopathic arthritis","volume":"26","author":"Chen","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1111\/1756-185X.70002","article-title":"JIA, today and tomorrow","volume":"27","author":"Zhang","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.866038","article-title":"Paradoxical effects of anti-TNF-\u03b1 agents in inflammatory diseases","volume":"10","author":"Wendling","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2467179","article-title":"An update on the safety of biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis","volume":"24","author":"Zimmer","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103332","DOI":"10.1016\/j.autrev.2023.103332","article-title":"Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders","volume":"22","author":"De Stefano","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1016\/j.jaip.2024.07.002","article-title":"Interleukin (IL)-1\/IL-6-inhibitor-associated drug reaction with eosinophilia and systemic symptoms (DReSS) in systemic inflammatory illnesses","volume":"12","author":"Saper","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000522","article-title":"Drug-induced lupus erythematosus: an update on drugs and mechanisms","volume":"30","author":"He","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11926-016-0588-6","article-title":"Biological therapy-induced systemic vasculitis","volume":"18","author":"Guti\u00e9rrez-Gonz\u00e1lez","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01042-z","article-title":"Treatment of systemic juvenile idiopathic arthritis","volume":"19","author":"Hinze","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091351","article-title":"State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies","volume":"8","author":"Andr\u00e8s","year":"2019","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaci.2021.11.011","article-title":"Autoimmune consequences of biologics","volume":"149","author":"Dhital","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25129","article-title":"Incidence and risk factors for eosinophilia and lung disease in biologic-exposed children with systemic juvenile idiopathic arthritis","volume":"75","author":"Wobma","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000446","article-title":"Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach","volume":"3","author":"Saunier","year":"2017","journal-title":"RMD Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12782","article-title":"The impact of disease activity and tumour necrosis factor-\u03b1 inhibitor therapy on cytokine levels in juvenile idiopathic arthritis","volume":"184","author":"Walters","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roae050","article-title":"Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: A systematic review","volume":"35","author":"Ishikawa","year":"2024","journal-title":"Mod Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu214","article-title":"Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database","volume":"53","author":"Moulis","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","article-title":"IL-6: a cytokine at the crossroads of autoimmunity","volume":"55","author":"Jones","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.129.667","article-title":"New therapeutic strategy for autoimmune and chronic inflammatory disease based on clinical results using IL-6 blocking therapy with a humanized anti-IL-6 receptor antibody","volume":"129","author":"Yoshizaki","year":"2009","journal-title":"Yakugaku Zasshi"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1744226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:36:01Z","timestamp":1768286161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1744226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1744226"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1744226","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1744226"}}